1. Home
  2. GNPX vs EDVA Comparison

GNPX vs EDVA Comparison

Compare GNPX & EDVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$1.68

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

EDVA

Endovia Health Sciences Inc. Common Stock

N/A

Current Price

$0.14

Market Cap

2.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
EDVA
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.0M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
GNPX
EDVA
Price
$1.68
$0.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
110.6K
★ 508.8K
Earning Date
11-13-2026
12-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.30
EPS
N/A
★ N/A
Revenue
N/A
★ $73,066.00
Revenue This Year
N/A
$24,377.87
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.42
$0.13
52 Week High
$9.99
$0.33

Technical Indicators

Market Signals
Indicator
GNPX
EDVA
Relative Strength Index (RSI) 31.86 38.24
Support Level $0.80 $0.14
Resistance Level $2.42 $0.19
Average True Range (ATR) 0.19 0.02
MACD -0.01 -0.00
Stochastic Oscillator 2.80 8.51

Price Performance

Historical Comparison
GNPX
EDVA

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About EDVA Endovia Health Sciences Inc. Common Stock

Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.

Share on Social Networks: